Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial.
Tobias HeerMoritz von ScheidtAndreas BoeningClarissa HeykenFriederike GusminiAntoinette de WahaConstantin KunaAndreas FachChristina GrothusenMartin OberhofferChristoph KnosallaThomas WaltherBernhard C DannerMartin MisfeldGerhard Wimmer-GreineckerMatthias SiepeHerko GrubitzschAlexander JoostAndreas SchaeferLenard ConradiJochen CremerChristian W HammRüdiger LangePeter W RadkeRainer SchulzGünther LauferPhilippe GrieshaberTim AttmannMichael SchmoeckelAlexander MeyerTibor ZiegelhöfferRainer HambrechtSigrid E SandnerAdnan KastratiHeribert SchunkertUwe ZeymerPublished in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2022)
Only every second patient receives optimal secondary prevention after CABG. Guideline adherent secondary prevention therapy is associated with lower mid-term mortality and less adverse cardiovascular events after 12 months.